GlaxoSmithKline plc / Theravance, Inc.

Chronic Obstructive Pulmonary Disease (COPD) and Asthma

$22.0B Global inhaled bronchodilator/respiratory market (broader category, contemporary)

Disease Overview

COPD and asthma are chronic obstructive airway diseases treated primarily with inhaled bronchodilators (LABA, LAMA) and inhaled corticosteroids (ICS), often combined into dual or triple-therapy inhalers. COPD alone affects an estimated 11-16M US adults and is the third leading cause of death in the US.

Competitive Landscape

In 2012, the inhaled respiratory market was dominated by GSK's Advair/Seretide (fluticasone propionate/salmeterol), AstraZeneca's Symbicort (budesonide/formoterol), and Boehringer Ingelheim's Spiriva (tiotropium LAMA), with Novartis (Onbrez/indacaterol) and Forest/Almirall's Tudorza in earlier launch phases. Advair's looming patent cliff drove GSK's urgency to advance Theravance-partnered next-gen inhalers: Relovair (later Breo Ellipta, FF/VI ICS/LABA), Anoro (UMEC/VI LAMA/LABA), and the triple FF/UMEC/VI (Trelegy Ellipta). The $213M equity investment raising GSK's stake from 18.3% to ~26.8% deepened economic alignment ahead of the FDA filings for FF/VI and UMEC/VI. The deal change: it consolidated GSK's claim on the once-daily ICS/LABA/LAMA franchise that ultimately generated Trelegy as a multi-billion-dollar asset (Royalty Pharma later paid $1.1B for 85% of Theravance's Trelegy royalty in 2022), validating the strategic logic. Risk at the time: trial readouts and FDA reception of the ICS/LABA class amid Advair safety scrutiny.